The success of recent initiatives aimed at creating more new treatments depends on bridging sociological divides in drug discovery and development. The 50th issue of Nature Reviews Drug Discovery prompted reflection on whether the journal's original mission—fostering communication between disciplines in drug discovery—remains relevant. Despite 50 years, the need to break down 'compartmentalization' remains critical as the pharmaceutical industry faces unprecedented pressure, with low numbers of new drug approvals and weakened earnings. While companies are investing heavily in R&D and exploring strategies like mergers and outsourcing, these efforts may not be sufficient without addressing outdated methodologies. Reducing technological gaps requires greater cooperation, including between competitors, which could lead to significant sociological changes. Examples include the Predictive Safety Testing Consortium and the Center for Biomedical Innovation, which aim to foster collaboration. However, true progress requires commitment across sectors, particularly between academic and industry scientists. Academic and industry scientists must overcome stereotypes and recognize each other's strengths. Industry needs to be more open to external creativity, while academia must understand industry timelines. Sociological change is challenging, but uniting around scientific philosophies rather than 'tribes' could help. If academia and industry remain divided, the future of drug discovery and development may continue to suffer.The success of recent initiatives aimed at creating more new treatments depends on bridging sociological divides in drug discovery and development. The 50th issue of Nature Reviews Drug Discovery prompted reflection on whether the journal's original mission—fostering communication between disciplines in drug discovery—remains relevant. Despite 50 years, the need to break down 'compartmentalization' remains critical as the pharmaceutical industry faces unprecedented pressure, with low numbers of new drug approvals and weakened earnings. While companies are investing heavily in R&D and exploring strategies like mergers and outsourcing, these efforts may not be sufficient without addressing outdated methodologies. Reducing technological gaps requires greater cooperation, including between competitors, which could lead to significant sociological changes. Examples include the Predictive Safety Testing Consortium and the Center for Biomedical Innovation, which aim to foster collaboration. However, true progress requires commitment across sectors, particularly between academic and industry scientists. Academic and industry scientists must overcome stereotypes and recognize each other's strengths. Industry needs to be more open to external creativity, while academia must understand industry timelines. Sociological change is challenging, but uniting around scientific philosophies rather than 'tribes' could help. If academia and industry remain divided, the future of drug discovery and development may continue to suffer.